Hyperactivity News and Research

RSS

CAMFT launches new searchable online directory for counselors and therapists

Taking control of your mental health and finding the support you need just got easier for Californians thanks to a new searchable online directory, CounselingCalifornia.com. The free service created by the California Association of Marriage and Family Therapists (CAMFT) addresses a significant hurdle for Californians looking for counselors and therapists.

4 Jan 2011

mTORC1 cellular pathway affects aging phenotype

Whitehead Institute researchers have linked hyperactivity in the mechanistic target of rapamycin complex 1 (mTORC1) cellular pathway, to reduced ketone production, which is a well-defined physiological trait of aging in mice.

23 Dec 2010

Study examines treatment options for children diagnosed with ADHD

For doctors and parents to jointly decide how to attack pediatric conditions, such as attention-deficit/hyperactivity disorder (ADHD), practical barriers to recommended health treatments need to be overcome, according to a study by The Children's Hospital of Philadelphia. In considering their options, parents preferred their physicians to offer an unbiased presentation of all available treatments.

21 Dec 2010

Scientists boost protein supply to enhance muscle function, reduce nerve-dependent fatigue in mice

Researchers at Vanderbilt University have "engineered" a mouse that can run on a treadmill twice as long as a normal mouse by increasing its supply of acetylcholine, the neurotransmitter essential for muscle contraction.

21 Dec 2010

Quality of care for ADHD children poor under Medicaid, says new report

Whatever its final incarnation, the recently enacted landmark Patient Protection and Affordable Care Act will expand Medicaid eligibility and is expected by 2013 to provide coverage, including mental health care, to an estimated 4.1 million children currently uninsured.

13 Dec 2010

Pisgah's technology imparts abuse deterrence to commonly abused prescription drugs

Pisgah Labs announced today the findings from a proof of concept study confirming Pisgah's technology imparts abuse deterrence to commonly abused prescription drugs, particularly narcotics. The controlled study, conducted in dogs, was performed with the un-formulated active ingredient, hydrocodone, as modified according to a host of patent applications filed by Pisgah Labs with the United States Patent and Trademark Office (http://www.uspto.gov).

10 Dec 2010

New software may help improve major deficiencies in ADHD children

An intensive, five-week working memory training program shows promise in relieving some of the symptoms of attention deficit hyperactivity disorder in children, a new study suggests.

10 Dec 2010

Urgent reform of Medicaid-financed community care for ADHD children needed

The enactment of the Patient Protection and Affordable Care Act of 2010 expands Medicare benefits to scores of previously uninsured individuals including many of our nation's children. While access to treatment is laudable, the quality of such treatment is the subject of an article in the December issue of the Journal of the American Academy of Child and Adolescent Psychiatry.

9 Dec 2010

ADHD, developmental RD have common genetic influences: Study

Attention Deficit Hyperactivity Disorder and developmental reading disability are complex childhood disorders that frequently occur together; if a child is experiencing trouble with reading, symptoms of ADHD are often also present.

9 Dec 2010

Intellipharmaceutics files generic 30 mg Focalin XR ANDA with FDA

Intellipharmaceutics International Inc., today announced that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for approval to market a generic of the 30 mg strength of Focalin XR® (dexmethylphenidate hydrochloride). The application for the 30 mg strength is filed as an amendment to the ANDA that Intellipharmaceutics had previously filed for the 5, 10, 15 and 20 mg strengths of the drug.

7 Dec 2010

ADHD drug market will decrease from $5 billion in 2009 to $4.1 billion in 2019: Report

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the attention-deficit/hyperactivity disorder (ADHD) drug market in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan will fluctuate modestly over the next decade, decreasing from $5 billion in 2009 to a trough in 2013 before climbing to $4.1 billion in 2019.

7 Dec 2010

Exposure to nicotine during pregnancy may cause learning disabilities in children: Research

Exposure to nicotine during pregnancy leads to a decrease in adult stem cells and a change in synaptic plasticity in the hippocampus of the offspring, according to new research from the University of Alabama at Birmingham presented at Neuroscience 2010, the annual Society for Neuroscience meeting in San Diego in November.

4 Dec 2010

Impax confirms challenge of patents in connection with INTUNIV

Impax Laboratories, Inc. today confirms that it has initiated a challenge of patents listed by Shire Development Inc. in connection with INTUNIVTM (guanfacine hydrochloride), 4 mg.

3 Dec 2010

Relationship-strengthening class for expectant, first-time parents improves family life

Expectant parents who completed a brief relationship-strengthening class around the time their child was born showed lasting effects on each family member's well being and on the family's overall relationships, according to a recent Penn State study.

3 Dec 2010

Soy bean derived compound could treat Sanfilippo genetic disease in children

Scientists from The University of Manchester say a naturally occurring chemical found in soy could prove to be an effective new treatment for a fatal genetic disease that affects children.

2 Dec 2010

Group drumming can improve social, emotional behavior in low-income children: NAMM Foundation

The NAMM Foundation today announced the findings of a recent study that shows how group drumming can improve social and emotional behavior in low-income children.

30 Nov 2010

Alza files patent infringement suit against Impax in connection with Concerta

Impax Laboratories, Inc. today confirms that Alza Corporation has filed suit for patent infringement against Impax in the United States District Court for the District of Delaware in connection with Concerta® (methylphenidate hydrochloride) extended-release 54 mg tablets.

30 Nov 2010

Shire announces FDA approval of Vyvanse Capsules CII for ADHD in adolescents

Shire plc, the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the prescription medication Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents ages 13 to 17. The approval is based on study data demonstrating that Vyvanse improved ADHD symptoms compared to placebo in adolescents with ADHD. Vyvanse is also indicated for the treatment of ADHD in children ages 6 to 12 years, and adults.

15 Nov 2010

Forest enters commercialization collaboration with Janssen for Bystolic and Savella in Canada

Forest Laboratories, Inc. announced that Forest Laboratories Holdings Limited, its wholly owned subsidiary, has entered into a definitive collaboration and distribution agreement for Bystolic® (nebivolol) and Savella® (milnacipran HCl) in Canada with Janssen Pharmaceutica, NV and Janssen Pharmaceutical respectively, on behalf of Janssen Inc., which will market the products in Canada.

12 Nov 2010

Children with hypertension more likely to have learning disabilities, ADHD

Children who have hypertension are much more likely to have learning disabilities than children with normal blood pressure, according to a new University of Rochester Medical Center (URMC) study published this week in the journal, Pediatrics. In fact, when variables such as socio-economic levels are evened out, children with hypertension were four times more likely to have cognitive problems.

10 Nov 2010